Niche-Targeted YAP/TAZ Activation Offers New Paradigm for Bone Marrow Regeneration After Myeloablative Therapy
Key Insights
Researchers identified YAP (search)/TAZ (search) transcriptional co-activators as essential regulators of bone marrow niche recovery following radiation and chemotherapy-induced injury, with knockout in MSCs and ECs significantly impairing hematopoietic regeneration.
A small molecule called GA-003 that inhibits LATS1/2 (search) kinase and activates YAP (search)/TAZ (search) was shown to accelerate BM niche recovery, enhance hematopoietic regeneration, and promote engraftment after HSC transplantation in mouse models.
GA-003 acted synergistically with granulocyte colony-stimulating factor (search) (G-CSF) to further enhance white blood cell recovery, suggesting combination potential for managing neutropenia.
A team led by Professor Atsushi Iwama at The Institute of Medical Science, The University of Tokyo (search), has demonstrated that pharmacologically activating the transcriptional co-activators YAP (search) and TAZ (search) in the bone marrow niche can significantly accelerate hematopoietic regeneration following myeloablative injury. The findings, published in the journal Blood on June 22, 2026, introduce a paradigm-shifting therapeutic strategy that targets the bone marrow microenvironment rather than hematopoietic stem cells themselves.
The research addresses a critical unmet need in oncology and hematology: myelosuppression (search), the depletion of hematopoietic cells including HSCs caused by radiation and chemotherapy. In severe cases, patients require HSC transplantation to restore blood cell production. However, the supporting cells of the bone marrow niche—endothelial cells and mesenchymal stromal cells—are also damaged during these treatments, and their poor recovery can undermine both chemotherapy and HSCT efficacy. Until now, therapeutic strategies specifically targeting niche recovery have remained underdeveloped.
YAP (search)/TAZ (search) Are Essential for Niche-Mediated Hematopoietic Recovery
Using a series of genetically engineered mouse models, the researchers knocked out YAP (search)/TAZ (search) genes specifically in endothelial cells, mesenchymal stromal cells, or hematopoietic cells. Under steady-state conditions, mice lacking YAP/TAZ in MSCs exhibited reduced HSC numbers in the bone marrow and increased HSC mobilization into circulating blood, establishing that basal YAP/TAZ activity in MSCs is essential for retaining HSCs in the bone marrow. In contrast, YAP/TAZ in hematopoietic cells was found to be largely dispensable under both steady-state and post-injury conditions.
When exposed to radiation, the differences became more pronounced. Hematopoietic recovery was significantly impaired in mice with YAP (search)/TAZ (search) knockout in MSCs, while loss of YAP/TAZ in ECs led to pronounced blood vessel dilation. These results indicate that YAP/TAZ in both MSCs and ECs plays a critical role in bone marrow niche recovery after injury.
Mechanistically, the study revealed that YAP (search)/TAZ (search) regulates key transcription factors including Ebf1 and Ebf3 in MSCs, preserving MSC identity and promoting the expression of hematopoietic factors such as Cxcl12 as well as angiogenic factors. Furthermore, YAP/TAZ in MSCs and ECs coordinately remodel sinusoidal vessels following bone marrow injury. Collectively, these YAP/TAZ-mediated niche responses are essential for hematopoietic regeneration following myeloablative therapies.
GA-003: A Small Molecule That Pharmacologically Activates YAP (search)/TAZ (search)
The researchers identified a small molecule called GA-003, which inhibits LATS1/2 (search) kinase and consequently increases YAP (search)/TAZ (search) activity. When administered to mice after radiation exposure, GA-003 significantly enhanced bone marrow niche recovery and accelerated hematopoietic regeneration. The compound also promoted engraftment following HSC transplantation and acted synergistically with granulocyte colony-stimulating factor (search), a drug commonly used to treat neutropenia, to further enhance white blood cell recovery.
"Our study may have significant impact by introducing a new therapeutic concept that targets the BM niche rather than hematopoietic cells themselves," said Professor Iwama. "It may stimulate further studies on microenvironment-driven regeneration involving similar signaling pathways in tissues."
Clinical Implications and Future Directions
The identification of pharmacological YAP (search)/TAZ (search) activation as a viable strategy provides a foundation for future drug development targeting tissue niches. The approach could potentially expand research into niche-targeted therapies across regenerative medicine and disease contexts, influencing a broad range of research fields by introducing a new conceptual framework that emphasizes the role of the tissue microenvironment in regeneration.
"Our new therapeutic approach addresses the limitation of supportive therapies and enhances the recovery of the BM niche, thereby enabling coordinated restoration of multiple blood cell lineages, including neutrophils, red blood cells, and platelets," concluded Professor Iwama. "This has the potential to improve the overall management of hematopoietic complications associated with chemotherapy, radiotherapy, and HSCT."
The study involved collaborators from The Institute of Medical Science at The University of Tokyo, St. Jude Children's Research Hospital in the United States, and Nissan Chemical Corporation (search) in Japan.